BioStock: Aptahem on the company's new research findings

Report this content

Aptahem has recently published an abstract containing data on its lead drug candidate Apta-1, which is being developed as an emergency treatment for sepsis. The abstract summarizes the current view of the effects of Apta-1 in vivo. The studies have identified Apta-1 as an anti-coagulant, an inhibitor of hyperinflammatory response and an inducer of tissue repair by significant increased levels of Pentraxin-3. BioStock contacted Aptahem CSO Luiza Jedlina and Anders Bylock, CMO and chairman of the company’s scientific advisory board, to find out more about the results. 

Read the full article and interview at

This is a press release from BioStock - Connecting Innovation & Capital.


Quick facts

BioStock: Aptahem on the company's new research findings
Tweet this


It is a very exciting result for any drug candidate to trigger a protein like Pentraxin-3 with such a broad spectrum of effects
Luiza Jedlina, CSO Aptahem